...well...the title speaks for itself
XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union (EU)
XTANDI can be given alone or in combination with androgen deprivation therapy
Approval is based on results from the positive Phase 3 EMBARK study which showed XTANDI alone or in combination with leuprolide reduced the risk of metastasis or death
Thus others in this class would be an equivalent. Possibly
my biggest confusion is if Xtandi fail, most of all MO is said all other medicine like darolutamide or apalutamide also fail. why there is no comparison available for all three
there is some comparison, what I think those MO say s that the AR inhibition is probably not working at large...but from what I know and read here, they would probably still try to switch medications
Per conversation with Dr. Sam Denmeade, there is reason to believe that BAT has in some cases the ability to resensitize the prostate cancer to AR inhibitors. "How many times can this done? we just don't know."
I am currently on mono enzalutimide per the EMBARK trial. I can only report positive results so far. Before looking for alternatives to Xtandi, I suggest giving it a go. Not everyone has the horrible SEs.
Short-term androgen annihilation in non-metastatic recurrent men delays progression
Thoughts? ADT following RT if PSA is already low (0 to 0.6)
Testosterone level while on ADT plus Xtandi
High Gleason low PSA - quit ADT? 
